(Q43739514)

English

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

scientific article

Statements

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial (English)
M J Ellis
L Mauriac
A Llombert-Cussac
F Jänicke
W R Miller
D B Evans
C Brady
E Quebe-Fehling
M Borgs
1 September 2001
3808-3816

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit